Assembly Biosciences (ASMB) Competitors $9.47 +0.08 (+0.85%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ASMB vs. NKTR, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Nektar Therapeutics Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Zoetis Royalty Pharma Nektar Therapeutics (NASDAQ:NKTR) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership. Do analysts recommend NKTR or ASMB? Nektar Therapeutics presently has a consensus target price of $4.92, indicating a potential upside of 646.08%. Assembly Biosciences has a consensus target price of $33.00, indicating a potential upside of 248.47%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Assembly Biosciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the MarketBeat Community favor NKTR or ASMB? Nektar Therapeutics received 393 more outperform votes than Assembly Biosciences when rated by MarketBeat users. Likewise, 70.78% of users gave Nektar Therapeutics an outperform vote while only 58.65% of users gave Assembly Biosciences an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63770.78% Underperform Votes26329.22% Assembly BiosciencesOutperform Votes24458.65% Underperform Votes17241.35% Does the media prefer NKTR or ASMB? In the previous week, Assembly Biosciences had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 8 mentions for Assembly Biosciences and 7 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.91 beat Assembly Biosciences' score of 0.54 indicating that Nektar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Assembly Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, NKTR or ASMB? Nektar Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Is NKTR or ASMB more profitable? Assembly Biosciences has a net margin of -144.05% compared to Nektar Therapeutics' net margin of -180.70%. Assembly Biosciences' return on equity of -121.46% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-180.70% -173.28% -46.31% Assembly Biosciences -144.05%-121.46%-34.56% Do insiders & institutionals have more ownership in NKTR or ASMB? 75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 3.7% of Nektar Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, NKTR or ASMB? Assembly Biosciences has lower revenue, but higher earnings than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$98.43M1.25-$276.06M-$0.59-1.12Assembly Biosciences$28.52M2.49-$61.23M-$6.72-1.41 SummaryNektar Therapeutics beats Assembly Biosciences on 12 of the 19 factors compared between the two stocks. Remove Ads Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.05M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-1.417.1123.1218.81Price / Sales2.49205.89369.1988.69Price / CashN/A65.6738.1634.64Price / Book1.266.146.704.18Net Income-$61.23M$142.11M$3.20B$247.10M7 Day Performance-12.40%-6.09%-4.00%-2.96%1 Month Performance-26.48%-10.87%-0.64%-6.48%1 Year Performance-29.85%-12.78%9.09%0.20% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences3.6959 of 5 stars$9.47+0.9%$33.00+248.5%-27.2%$71.05M$28.52M-1.41100NKTRNektar Therapeutics4.3658 of 5 stars$0.68-7.9%$4.92+623.0%-29.5%$126.55M$98.43M-0.81220CPIXCumberland Pharmaceuticals1.0146 of 5 stars$4.23-4.1%N/A+159.5%$59.09M$37.87M-5.4980LLYEli Lilly and Company4.8077 of 5 stars$825.42+0.4%$1,009.72+22.3%+5.8%$782.64B$45.04B70.4939,000JNJJohnson & Johnson4.704 of 5 stars$165.89+1.3%$171.33+3.3%-2.9%$399.76B$88.82B24.95152,700Analyst ForecastABBVAbbVie4.5288 of 5 stars$209.83+2.2%$211.45+0.8%+14.0%$371.19B$56.33B87.4350,000Positive NewsMRKMerck & Co., Inc.5 of 5 stars$89.74+0.6%$117.12+30.5%-33.5%$226.69B$64.17B13.3369,000Analyst RevisionPFEPfizer4.9858 of 5 stars$25.36+0.6%$31.92+25.9%-11.5%$143.80B$63.63B17.9883,000BMYBristol-Myers Squibb3.8977 of 5 stars$61.05+1.7%$57.86-5.2%+12.4%$123.89B$48.30B-13.8134,300Short Interest ↑Analyst RevisionPositive NewsZTSZoetis4.6127 of 5 stars$164.54+0.9%$215.90+31.2%-3.1%$73.68B$9.26B30.0814,100Positive NewsRPRXRoyalty Pharma4.8772 of 5 stars$31.13-0.8%$41.60+33.6%+4.2%$17.94B$2.26B21.4780Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Nektar Therapeutics Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol-Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASMB) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASMB Stock Free ASMB Stock Alerts